Education
About Us
Working with TipRanks
Follow Us
Kazia Therapeutics Limited (KZIA)
NASDAQ:KZIA
KZIA Stock Chart & Stats
$6.44
-$0.01(-0.57%)
At close: 4:00 PM EST
$6.44
-$0.01(-0.57%)
Day’s Range― - ―
52-Week Range$2.86 - $17.40
Previous CloseN/A
Volume31.49K
Average Volume (3M)209.48K
Market Cap
$60.53M
Enterprise Value$9.37M
Total Cash (Recent Filing)$4.34M
Total Debt (Recent Filing)$396.00K
Price to Earnings (P/E)―
Beta1.69
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,335,992
10 Day Avg. Volume60,839
30 Day Avg. Volume209,481
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-1.26
Price to Sales (P/S)248.45
P/FCF Ratio-0.79
Enterprise Value/Market Cap0.15
Enterprise Value/Revenue222.99
Enterprise Value/Gross Profit222.99
Enterprise Value/Ebitda-0.71
Forecast
1Y Price Target
$19.00Price Target Upside195.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy In Triple-negative Breast CancerAnalyst notes early clinical activity in triple-negative breast cancer with multiple partial responses and a confirmed complete metabolic response in a patient who had progressed on pembrolizumab plus chemotherapy, indicating meaningful anti-tumor effects in difficult cases.
Expansion Into Additional Breast Cancer IndicationsClinical signals in both triple-negative and HER2‑positive breast cancer suggest paxalisib could expand the drug's commercial opportunity beyond glioblastoma by acting as an immuno-oncology enabler and reducing metastatic circulating tumor cell clusters.
Improved Financial RunwayAn equity raise of about $50 million and a cash runway extending into 2027 materially reduce near-term financing pressure and support continued clinical development across multiple studies.
Bears Say
Market-driven Share VolatilityHeavy sell-the-news activity and short-term selling behavior have driven sharp share declines, increasing stock volatility even amid positive clinical updates.
Operational, Commercial And IP RisksA range of downside risks—including potential clinical setbacks, commercial execution challenges, partnership issues, and intellectual property hurdles—could negatively affect valuation and future prospects.
Regulatory Uncertainty For Accelerated ApprovalMissing the primary endpoint for the accelerated approval path creates uncertainty around regulatory success and could delay or complicate any potential approval timeline.
Kazia Therapeutics News
KZIA FAQ
What was Kazia Therapeutics Limited’s price range in the past 12 months?
Kazia Therapeutics Limited lowest stock price was $2.86 and its highest was $17.40 in the past 12 months.
What is Kazia Therapeutics Limited’s market cap?
Kazia Therapeutics Limited’s market cap is $60.53M.
When is Kazia Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Kazia Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is Kazia Therapeutics Limited overvalued?
According to Wall Street analysts Kazia Therapeutics Limited’s price is currently Undervalued.
Does Kazia Therapeutics Limited pay dividends?
Kazia Therapeutics Limited does not currently pay dividends.
What is Kazia Therapeutics Limited’s EPS estimate?
Kazia Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kazia Therapeutics Limited have?
Kazia Therapeutics Limited has 11,335,992 shares outstanding.
What happened to Kazia Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kazia Therapeutics Limited?
Currently, no hedge funds are holding shares in KZIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kazia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.00 (195.03% Upside)
$19.00 (195.03% Upside)
Hedge Fund Trend
Decreased
By 36.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-73.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-33.34%
Trailing 12-Months
Company Description
Kazia Therapeutics Limited
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
KZIA Stock 12 Month Forecast
Average Price Target
$19.00
▲(195.03% Upside)
Technical Analysis
Phio Pharmaceuticals
―
XTL Biopharmaceuticals Sponsored ADR
―
Marker Therapeutics
―
Galecto
―
TransCode Therapeutics
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.07% Other Institutional Investors
99.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---